Other
Autoimmunity
9
Pipeline Programs↗
6
Active Trials↗
7
Companies Involved↗
Autoimmunity is an early-stage landscape with 9 programs across 7 companies. The most active players are Roche, TG Therapeutics, Inc., Iovance Biotherapeutics, Inc.. 3 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 24
Analysis
Modality Breakdown
7programs
Small molecule343%
Monoclonal antibody343%
Protein / enzyme114%
Modality classified for 100% of 11 pipeline programs.
Analysis
Trial Status
12
clinical trials
Active, not recruiting3 · 25%
Unknown status3 · 25%
Withdrawn2 · 17%
Recruiting2 · 17%
Not yet recruiting1 · 8%
Terminated1 · 8%
Clinical Trials
Trial Activity
12 trials
Effect of Prednisone and Aspirin on IVF-ET Outcome Among Patients With Thyroid Autoimmunity
Not yet recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05578456·540 enrolled
Autoimmunity in Inner Ear Disease
Terminated·National Institute on Deafness and Other Communication Disorders (NIDCD)·Phase 3·NCT00000361
An Assessment of Aspirin Plus Prednisone Treatment for Euthyroid Women With Thyroid Autoimmunity
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·N/A·NCT04943146·402 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)